KalVista Pharmaceuticals KALV Stock
KalVista Pharmaceuticals Price Chart
KalVista Pharmaceuticals KALV Financial and Trading Overview
| KalVista Pharmaceuticals stock price | 13 USD |
| Previous Close | 9.6 USD |
| Open | 9.58 USD |
| Bid | 0 USD x 1000 |
| Ask | 0 USD x 1000 |
| Day's Range | 9.28 - 9.69 USD |
| 52 Week Range | 4.12 - 17.06 USD |
| Volume | 120.49K USD |
| Avg. Volume | 231.33K USD |
| Market Cap | 329.05M USD |
| Beta (5Y Monthly) | 1.103521 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.77 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 19.33 USD |
KALV Valuation Measures
| Enterprise Value | 165.84M USD |
| Trailing P/E | N/A |
| Forward P/E | -3.3092782 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 1.7820134 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | -1.575 |
Trading Information
KalVista Pharmaceuticals Stock Price History
| Beta (5Y Monthly) | 1.103521 |
| 52-Week Change | 5.59% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 17.06 USD |
| 52 Week Low | 4.12 USD |
| 50-Day Moving Average | 9.24 USD |
| 200-Day Moving Average | 8.12 USD |
KALV Share Statistics
| Avg. Volume (3 month) | 231.33K USD |
| Avg. Daily Volume (10-Days) | 183.11K USD |
| Shares Outstanding | 34.17M |
| Float | 19.66M |
| Short Ratio | 16.17 |
| % Held by Insiders | 0.87% |
| % Held by Institutions | 103.80% |
| Shares Short | 3.59M |
| Short % of Float | 11.09% |
| Short % of Shares Outstanding | 10.51% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:14 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | April 30, 2022 |
| Most Recent Quarter (mrq) | January 31, 2023 |
| Next Fiscal Year End | April 30, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -30.90% |
| Return on Equity (ttm) | -46.23% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | -70167000 USD |
| EBITDA | -105268000 USD |
| Net Income Avi to Common (ttm) | -90715000 USD |
| Diluted EPS (ttm) | -3.55 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 171.68M USD |
| Total Cash Per Share (mrq) | 5.03 USD |
| Total Debt (mrq) | 8.48M USD |
| Total Debt/Equity (mrq) | 4.6 USD |
| Current Ratio (mrq) | 16.555 |
| Book Value Per Share (mrq) | 5.404 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -79414000 USD |
| Levered Free Cash Flow (ttm) | -55472248 USD |
Profile of KalVista Pharmaceuticals
| Country | United States |
| State | MA |
| City | Cambridge |
| Address | 55 Cambridge Parkway |
| ZIP | 02142 |
| Phone | 857 999 0075 |
| Website | https://www.kalvista.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 105 |
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, a plasma kallikrein inhibitor that completed a Phase II clinical trial for the treatment of DME; sebetralstat, which is initiation of the Phase 3 KONFIDENT trial as a potential oral, on-demand therapy for HAE attacks; KVD824, an oral product candidate for the treatment of HAE; and Factor XIIa, an oral inhibitor program which is in preclinical stage targets an enzyme in HAE. The company is headquartered in Cambridge, Massachusetts.
Q&A For KalVista Pharmaceuticals Stock
What is a current KALV stock price?
KalVista Pharmaceuticals KALV stock price today per share is 13 USD.
How to purchase KalVista Pharmaceuticals stock?
You can buy KALV shares on the NasdaqGM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for KalVista Pharmaceuticals?
The stock symbol or ticker of KalVista Pharmaceuticals is KALV.
Which industry does the KalVista Pharmaceuticals company belong to?
The KalVista Pharmaceuticals industry is Biotechnology.
How many shares does KalVista Pharmaceuticals have in circulation?
The max supply of KalVista Pharmaceuticals shares is 49.72M.
What is KalVista Pharmaceuticals Price to Earnings Ratio (PE Ratio)?
KalVista Pharmaceuticals PE Ratio is now.
What was KalVista Pharmaceuticals earnings per share over the trailing 12 months (TTM)?
KalVista Pharmaceuticals EPS is -3.77 USD over the trailing 12 months.
Which sector does the KalVista Pharmaceuticals company belong to?
The KalVista Pharmaceuticals sector is Healthcare.
KalVista Pharmaceuticals KALV included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 17366.13 USD — |
-0.1
|
9.58B USD — | 17128.71 USD — | 17467.35 USD — | — - | 9.58B USD — |
| NASDAQ Global Market Composite NQGM | 1854.61 USD — |
+0.81
|
— — | 1835.2 USD — | 1871.93 USD — | — - | — — |
| NASDAQ Biotechnology NBI | 4184.77 USD — |
+1.29
|
— — | 4144.83 USD — | 4202.15 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 931.02 USD — |
+0.81
|
— — | 921.75 USD — | 934.48 USD — | — - | — — |
| Stlmt ID NASDAQ Biotechnology NBX | 4157.43 USD — |
+0.21
|
— — | 3927.42 USD — | 4157.43 USD — | — - | — — |
- {{ link.label }} {{link}}